A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB (R), Both Co-administered With Prevnar 13 (R) at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13 (R)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2013
At a glance
- Drugs Haemophilus b CRM197 conjugate vaccine (HibTITER) (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Infections
- Focus Adverse reactions
- 20 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Sep 2013 Planned end date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 19 Apr 2013 Planned end date changed from 1 Apr 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.